|
Market Closed -
Nasdaq
23:00:00 04/09/2026 +03
|
5-day change | 1st Jan Change | ||
| 487.61 USD | -0.54% |
|
-4.46% | +0.07% |
| 02:00pm | Roivant's experimental lung disease drug meets goals in mid-stage study | RE |
| 09-02 | United Therapeutics Insider Sold Shares Worth $4,883,839, According to a Recent SEC Filing | MT |
| Market Cap | 20.91B 17.99B 16.92B 15.44B 28.88B 1,978B 28.97B 201B 77.53B 1,013B 78.54B 76.82B 3,226B | P/E 2026 * |
18.7x | P/E 2027 * | 17x |
|---|---|---|---|---|---|
| Enterprise Value | 17.94B 15.43B 14.51B 13.25B 24.78B 1,697B 24.86B 172B 66.51B 869B 67.38B 65.9B 2,768B | EV / Sales 2026 * |
5.71x | EV / Sales 2027 * | 4.97x |
| Free-Float |
53.72% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| UTHR | Delayed | |
CBOE
| UTHR | Real-time | |
|
Tradegate
| UTH | Real-time | |
|
Mexican S.E.
| UTHR * | End-of-day quote | |
|
Deutsche Boerse AG
| UTH | Delayed | |
|
Börse Stuttgart
| UTH | Delayed | |
|
Boerse Muenchen
| UTH | Real-time | |
|
Berne S.E.
| UTH | End-of-day quote |
Last Transcript : United Therapeutics Corporation
| 1 day | -0.54% | ||
| 1 week | -4.46% | ||
| Current month | -4.46% | ||
| 1 month | -9.51% | ||
| 3 months | -11.32% | ||
| 6 months | +1.98% | ||
| Current year | +0.07% |
| 1 week | 477.01 |  | 510.05 |
| 1 month | 477.01 | | 540.56 |
| Current year | 455.63 | | 609.35 |
| 1 year | 392.17 | | 609.35 |
| 3 years | 208.62 | | 609.35 |
| 5 years | 158.38 | | 609.35 |
| 10 years | 74.31 | | 609.35 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 71 | 26/06/1996 | |
| President | 54 | 26/06/2016 | |
James Edgemond
DFI | Director of Finance/CFO | 58 | 13/03/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Raymond Kurzweil
BRD | Director/Board Member | 78 | 01/01/2002 |
| Chairman | 71 | 26/06/1996 | |
Louis Sullivan
BRD | Director/Board Member | 92 | 01/01/2002 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 9/3/26 A | Exercice | Chief Executive Officer | 28,500 | 0.0671% | ||
| 9/3/26 A | Exercice | General Counsel | 24,900 | 0.0587% | ||
| 9/2/26 A | Exercice | Chief Executive Officer | 28,500 | 0.0671% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.54% | -4.46% | +21.74% | +119.02% | 20.91B | |
| -0.88% | -0.64% | +58.05% | +100.51% | 1,024B | |
| -1.15% | +3.53% | +54.25% | +71.99% | 663B | |
| -1.44% | +0.02% | +20.65% | +72.22% | 453B | |
| -0.45% | +1.35% | +30.40% | +37.20% | 349B | |
| -9.11% | -13.07% | +11.26% | +29.19% | 295B | |
| -0.95% | -0.09% | -0.15% | +10.19% | 253B | |
| -1.55% | +1.71% | +54.15% | +71.87% | 236B | |
| -0.94% | +0.82% | -14.60% | -56.27% | 206B | |
| -0.15% | +3.18% | +31.24% | +104.21% | 187B | |
| Average | -1.94% | +0.51% | +26.70% | +56.01% | 368.82B | |
| Weighted average by Cap. | -1.62% | +0.49% | +36.55% | +63.73% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 3.14B 2.7B 2.54B 2.32B 4.34B 297B 4.35B 30.11B 11.64B 152B 11.79B 11.53B 484B | 3.44B 2.96B 2.78B 2.54B 4.75B 325B 4.77B 33.01B 12.76B 167B 12.93B 12.64B 531B |
| Net income | 1.2B 1.03B 969M 884M 1.65B 113B 1.66B 11.48B 4.44B 57.99B 4.5B 4.4B 185B | 1.32B 1.13B 1.07B 973M 1.82B 125B 1.83B 12.64B 4.88B 63.82B 4.95B 4.84B 203B |
| Net Debt | -2.97B -2.56B -2.4B -2.19B -4.1B -281B -4.12B -28.51B -11.02B -144B -11.16B -10.92B -459B | -3.81B -3.27B -3.08B -2.81B -5.26B -360B -5.27B -36.5B -14.11B -184B -14.29B -13.98B -587B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/09/26 | $487.61 | -0.54% | 327,024 |
| 03/09/26 | $490.24 | -0.36% | 469,576 |
| 02/09/26 | $492.02 | -4.03% | 1,404,131 |
| 01/09/26 | $512.70 | +0.45% | 478,996 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- UTHR Stock
Select your edition
All financial news and data tailored to specific country editions
